This post was written and published as a collaboration between the in-house editorial team at Benzinga and Tonix ...

The CD40/CD40 ligand (CD40L) costimulatory system, which amplifies immune responses and can induce inflammation, is believed to have a role in skin manifestations of other autoimmune diseases ...

Company expects to have sufficient cash to fund planned operations beyond the FDA PDUFA goal date and anticipated fourth quarter 2025 launch of TNX-102 SL for fibromyalgia; $98.8 million in cash as of ...

Tegoprubart, an anti-CD40L antibody, plays a crucial role in the immunosuppression regimen to prevent organ rejection. Its design to block CD40L has shown promise in inhibiting immune cell ...

The work focuses on the interaction of B cells and T cells in the body's immune system via two proteins—CD40 on B cells and CD40L on T cells—in an immune deficiency disease called X-linked ...

Sanofi has posted encouraging results with one of its mid-stage candidates for multiple sclerosis, anti-CD40L antibody frexalimab, and says it plans to move the drug into a phase 3 programme next ...

The Company’s lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential. The ...